Blockchain Registration Transaction Record

Soligenix Advances Photodynamic Therapy for CTCL with HyBryte™ Milestone

Soligenix advances HyBryte™ photodynamic therapy for cutaneous T-cell lymphoma treatment. Learn about this selective cancer treatment approach and recent clinical trial milestones.

This development matters because photodynamic therapy represents a significant advancement in cancer treatment, particularly for conditions like cutaneous T-cell lymphoma where traditional treatments often cause severe side effects. The selectivity of PDT means it can target cancerous cells while sparing healthy tissue, potentially reducing treatment complications and improving quality of life for patients. For the approximately 3,000 people diagnosed with CTCL annually in the U.S., this could mean access to a more effective, less toxic treatment option. Beyond CTCL, successful development of photodynamic therapies could pave the way for similar approaches to other cancers and inflammatory conditions, potentially transforming treatment paradigms across multiple medical specialties.